Drug · CHEMBL905
RIZATRIPTAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. RIZATRIPTAN. Drugs and targets, record CHEMBL905. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL905
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HTR1B | 5-hydroxytryptamine receptor 1B | Serotonin 1b (5-HT1b) receptor agonist | AGONIST | https://conductscience.org/library/genes/3351 |
| HTR1D | 5-hydroxytryptamine receptor 1D | Serotonin 1d (5-HT1d) receptor agonist | AGONIST | https://conductscience.org/library/genes/3352 |
Source ChEMBL
Diseases4
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| migraine disorder | Approval | ATC and TTD | 23 | 21 | https://conductscience.org/library/drugs?q=MONDO_0005277 |
| Vertigo | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0002321 |
| migraine with aura | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005475 |
| motion sickness | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0006928 |
Source Open Targets
Trials24
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01286207 | Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) | Phase 3 | 1,959 | 2011-06-10 | rizatriptan | Its name | ClinicalTrials.gov |
| NCT03896009 | Maximizing Outcomes in Treating Acute Migraine | Phase 3 | 1,594 | 2023-08-24 | meloxicam and rizatriptan, rizatriptan | Its name | ClinicalTrials.gov |
| NCT01001234 | A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7) | Phase 3 | 1,382 | 2012-05-08 | rizatriptan | Its name | ClinicalTrials.gov |
| NCT00898677 | Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) | Phase 3 | 1,268 | 2009-07-14 | rizatriptan | Its name | ClinicalTrials.gov |
| NCT00897104 | MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029) | Phase 3 | 933 | 2010-07-23 | rizatriptan | Its name | ClinicalTrials.gov |
| NCT00899379 | Treatment of Multiple Attacks of Acute Migraine (0462-025) | Phase 3 | 473 | 2010-07-15 | rizatriptan | Its name | ClinicalTrials.gov |
| NCT00246337 | A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004) | Phase 2 | 420 | 2010-09-15 | rizatriptan | Its name | ClinicalTrials.gov |
| NCT00250458 | Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea | Phase 3 | 346 | 2010-06-23 | rizatriptan | Its name | ClinicalTrials.gov |
| NCT04163185 | Initiating Early Control of Migraine Pain and Associated Symptoms | Phase 3 | 302 | 2026-01-28 | rizatriptan | Its name | ClinicalTrials.gov |
| NCT02447991 | Rizatriptan for Episodic Dizziness in Vestibular Migraine | Phase 2/3 | 223 | 2021-11-04 | rizatriptan | Its name | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rizatriptan vs Placebo: serious adverse events | 0 of 462 | 2 of 515 | 977 | NCT01001234 | Trial comparisons |
| AXS-07 vs Placebo: Percentage of Subjects With Absence of Most Bothersome Symptom | 158 of 428 | 51 of 209 | 637 | NCT03896009 | Trial comparisons |
| AXS-07 vs Placebo: Percentage of Subjects Reporting Headache Pain Freedom | 85 of 428 | 14 of 209 | 637 | NCT03896009 | Trial comparisons |
| Rizatriptan 10 mg vs Placebo: serious adverse events | 0 of 337 | 0 of 84 | 421 | NCT00899379 | Trial comparisons |
| Rizatriptan 10 mg vs Placebo: serious adverse events | 0 of 200 | 0 of 97 | 297 | NCT00250458 | Trial comparisons |
| AXS-07 vs Placebo: deaths from any cause | 0 of 140 | 0 of 143 | 283 | NCT04163185 | Trial comparisons |
| AXS-07 vs Placebo: serious adverse events | 0 of 140 | 0 of 143 | 283 | NCT04163185 | Trial comparisons |
| AXS-07 vs Placebo: Percentage of Subjects Achieving Headache Pain Freedom at Hour 2 | 43 of 132 | 22 of 135 | 267 | NCT04163185 | Trial comparisons |
| AXS-07 vs Placebo: Percentage of Subjects With Absence of Most Bothersome Symptom at Hour 2 | 58 of 132 | 36 of 135 | 267 | NCT04163185 | Trial comparisons |
| Rizatriptan 27 Tablets - Clinical Limit vs Rizatriptan 9 Tablets - Formulary Limit: Adverse Experiences | 18 of 77 | 24 of 74 | 151 | NCT00397254 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials12
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL905
GET https://conductscience.org/api/drugs/v1/CHEMBL905/trials?page=2